JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

35.83 0.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

35.36

Max

36.39

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+44.41% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	645M 6.3B
Iepriekšējā atvēršanas cena	35.41
Iepriekšējā slēgšanas cena	35.83

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. apr. 23:08 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 23:07 UTC

Peļņas

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:20 UTC

Peļņas

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 23:48 UTC

Tirgus saruna

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026. g. 30. apr. 23:27 UTC

Tirgus saruna

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026. g. 30. apr. 23:22 UTC

Peļņas

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026. g. 30. apr. 23:20 UTC

Tirgus saruna

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026. g. 30. apr. 22:52 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:33 UTC

Peļņas

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026. g. 30. apr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026. g. 30. apr. 22:05 UTC

Peļņas

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 21:57 UTC

Peļņas

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026. g. 30. apr. 21:55 UTC

Peļņas

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026. g. 30. apr. 21:53 UTC

Peļņas

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

44.41% augšup

Prognoze 12 mēnešiem

Vidējais 51.8 USD 44.41%

Augstākais 64 USD

Zemākais 35 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.